Stablepharma Secures €2.5m EIC Accelerator Grant, Recognised Among Europe's Top 71 Innovators
19.2.2025 13:14:00 CET | Business Wire | Press release
UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant recognises the company’s cutting-edge fridge-free pharmaceutical technology, which meets EIC’s rigorous criteria for excellence, impact, and risk management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219452036/en/
Stablepharma Secures €2.5m EIC Accelerator Grant, Recognised Among Europe's Top 71 Innovators (Photo: Business Wire)
Stablepharma is among 71 companies from 16 countries across Europe selected for this highly competitive funding round, which saw a record 1,211 proposals submitted in 2024. This year’s EIC Accelerator grant marks the most competitive round in Horizon Europe’s history, underscoring the growing demand for innovative solutions across all sectors.
“This EIC Accelerator grant is a clear recognition of Stablepharma’s continued innovation and commitment to making fridge-free vaccines, therapeutics, and diagnostics a reality,” said Ozgur Tuncer, CEO & Executive Director of Stablepharma. “We are incredibly proud to be one of five UK companies awarded this grant. It serves as a testament to the quality and calibre of the UK’s Life Sciences industry and its ongoing advancements.”
Tuncer’s comments underscore the significance of the €2.5 million award, which acknowledges Stablepharma’s leading role in addressing the challenges associated with cold chain logistics, with its groundbreaking fridge-free technology.
The selected companies will collectively receive up to €161 million in grants. The equity investments will be made through the EIC Fund, the EIC’s dedicated investment arm and Europe’s largest deep-tech investor, which typically attracts additional investors and increases the overall investment to more than three times the EIC's original amount.
Stablepharma’s innovative technology platform, StablevaX™, transforms approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This innovation addresses a critical global challenge: the distribution, storage, and wastage issues associated with temperature-sensitive products reliant on the cold chain.
Dr. Steve Chatfield, Non-Executive Chairman of Stablepharma, commented, “We are delighted to have received this grant, given the quality of applicants across Europe. This is a huge accolade to the Stablepharma team who have worked tirelessly to progress our StablevaX™ technology.”
The grant comes as the company moves forward with accelerated Phase 1 clinical trials for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria vaccine in March 2025. The achievement marks a key milestone for Stablepharma, which is on track to revolutionize the global vaccine landscape with its innovative approach to vaccine storage and distribution.
The trial is expected to be completed by early Q3 2025, with results anticipated by Q4 2025, and was part funded by Innovate UK. Stablepharma’s projects align with their commitment to positively impact global health, reduce wastage and ensure equitable access of vaccines.
About Stablepharma:
Stablepharma’s R&D team has identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology. The company actively collaborates with global vaccine manufacturers, academic institutions and NGOs, to advance their pipeline of thermostable products.
StablevaX™ technology can be manufactured under scalable GMP conditions, enabling scale-up of the manufacturing process to provide millions of doses annually.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219452036/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom